Low immunogenicity but reduced bioavailability of an interferon beta-1a biosimilar compared with its biological parent: results of MATRIX, a cross-sectional, multicenter phase 4 study

References

• Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996;39(3):285–294.
   PubMed Web of Science ®Google Scholar
• PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet. 1998;352(9139):1498–1504. [published correction appears in Lancet. 1999;353(9153):678].
   PubMed Web of Science ®Google Scholar
• Meager A, Dolman C, Dilger P, et al. An assessment of biological potency and molecular characteristics of different innovator and noninnovator interferon-beta products. J Interferon Cytokine Res. 2011; 31(4):383–392.
   PubMed Web of Science ®Google Scholar
• Reingold SC, Steiner JP, Polman CH, et al. The challenge of follow-on biologics for treatment of multiple sclerosis. Neurology. 2009;73(7):552–559.
   PubMed Web of Science ®Google Scholar
• Rivera VM. The challenge of follow-on biologics for treatment of multiple sclerosis. Neurology. 2010;74(10):864.
   Web of Science ®Google Scholar
• Weise M, Bielsky MC, De SK, et al. Biosimilars-why terminology matters. Nat Biotechnol. 2011;29(8):690–693.
   PubMed Web of Science ®Google Scholar
• Deisenhammer F. Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes. CNS Drugs. 2009;23(5):379–396.
   PubMed Web of Science ®Google Scholar
• Malucchi S, Gilli F, Caldano M, et al. One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients. J Neurol. 2011;258(5):895–903.
   Web of Science ®Google Scholar
• Vartanian T, Solberg SP, Rice G. Impact of neutralizing antibodies on the clinical efficacy of interferon beta in multiple sclerosis. J Neurol. 2004;251(Suppl 2):II25–II30.
   Web of Science ®Google Scholar
• Balabanov P, Haas M, Elferink A, Bakchine S, Broich K. Addressing the regulatory and scientific challenges in multiple sclerosis – a statement from the EU regulators. Mult Scler. 2014;20(10):1282–1287.
   Web of Science ®Google Scholar
• European Medicines Agency. Guideline on similar biological medicinal products containing interferon beta. Available from: http://www.ema.europa.eu/docs/en_GB/_library/Scientific_guideline/2013/03/WC500139622.pdf. Accessed January 5, 2015.
   Google Scholar
• Scagnolari C, Bellomi F, Trombetti S, et al. Expression of biomarkers of interferon type I in patients suffering from chronic diseases. Clin Exp Immunol. 2007;147(2):270–276.
   PubMed Web of Science ®Google Scholar
• Murr C, Widner B, Wirleitner B, Fuchs D. Neopterin as a marker for immune system activation. Curr Drug Metab. 2002;3(2):175–187.
   PubMed Web of Science ®Google Scholar
• Casoni F, Merelli E, Bedin R, Sola P, Bertolotto A, Faglioni P. Is serum neopterin level a marker of responsiveness to interferon beta-1a therapy in multiple sclerosis? Acta Neurol Scand. 2004;109(1):61–65.
   PubMed Web of Science ®Google Scholar
• Avonex (interferon beta-1a) injection, for intramuscular injection [prescribing information]. Cambridge, MA: Biogen; 2014.
   Google Scholar
• Bertolotto A, Malucchi S, Sala A, et al. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J Neurol Neurosurg Psychiatry. 2002;73(2):148–153.
   PubMed Web of Science ®Google Scholar
• Grossberg SE, Oger J, Grossberg LD, Gehchan A, Klein JP. Frequency and magnitude of interferon beta neutralizing antibodies in the evaluation of interferon beta immunogenicity in patients with multiple sclerosis. J Interferon Cytokine Res. 2011;31(3):337–344.
   PubMed Web of Science ®Google Scholar
• Lam R, Farrell R, Aziz T, et al. Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients. J Immunol Methods. 2008;336(2):113–118.
   PubMed Web of Science ®Google Scholar
• Werner ER, Bichler A, Daxenbichler G, et al. Determination of neopterin in serum and urine. Clin Chem. 1987;33(1):62–66.
   Web of Science ®Google Scholar
• Kappos L, Clanet M, Sandberg-Wollheim M, et al; European Interferon Beta-1a IM Dose-Comparison Study Investigators. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology. 2005;65(1):40–47.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Questions and answers on the withdrawal of the marketing authorisation application for Biferonex (interferon beta-1a). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2010/01/WC500061395.pdf. Accessed January 5, 2015.
   Google Scholar